Novo Nordisk invests USD 2.6bn in new manufacturing facilities

The pharmaceutical company plans to build three new manufacturing facilities and to expand one factory in the Danish city of Kalundborg. Construction is anticipated to create around 400 new jobs.

Photo: Novo Nordisk / PR

With an investment of DKK 17bn (USD 2.6bn), Novo Nordisk seeks to strengthen all of the links in its global value chain, from drug production to packaging, it announces in a press release on Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs